Max Roessler

Contribution of Epigenetic Silencing of Tumor Necrosis Factor–Related Apoptosis Inducing Ligand Receptor 1 (DR4) to TRAIL Resistance and Ovarian Cancer

Peter Horak, Dietmar Pils, Griet Haller et al. · Molecular Cancer Research · 2005 · 148 citations · Full text

Medicine, Molecular Biology, Oncology +17

Open-label, randomized study of individualized, pharmacokinetically (PK)-guided dosing of paclitaxel combined with carboplatin or cisplatin in patients with advanced non-small-cell lung cancer (NSCLC)

Markus Joerger, Joachim von Pawel, Stefanie Kraff et al. · Annals of Oncology · 2016 · 89 citations

Pharmacy, Pharmacokinetics, Pharmacology +12

Prospective, Multicenter Study of 5-Fluorouracil Therapeutic Drug Monitoring in Metastatic Colorectal Cancer Treated in Routine Clinical Practice

Martin Wilhelm, Lothar Mueller, Michael Craig Miller et al. · Clinical Colorectal Cancer · 2016 · 68 citations

Medicine, Oncology, Pharmacology +15

Population Modeling Integrating Pharmacokinetics, Pharmacodynamics, Pharmacogenetics, and Clinical Outcome in Patients With Sunitinib‐Treated Cancer

Achim Fritsch, Friederike Kanefendt, JJ Swen et al. · CPT Pharmacometrics & Systems Pharmacology · 2017 · 34 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +16

Common death receptor 4 (DR4) polymorphisms do not predispose to ovarian cancer

Peter Horak, Dietmar Pils, Max Roessler et al. · Gynecologic Oncology · 2005 · 20 citations

Life Sciences, Genetics, Molecular Genetics +13